Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide-Reference-Cited by-同舟云学术

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide

Published:2022-02 Issue:6 Volume:73 Page:
ISSN:2724-6051
Container-title:Minerva Urology and Nephrology
language:
Short-container-title:Minerva Urol Nephrol

Author:

PISANO Chiara,TUCCI Marcello,DI STEFANO Rosario F.,TURCO Fabio,SAMUELLY Alessandro,BUNGARO Maristella,VIGNANI Francesca,TARENGHI Federica,SCAGLIOTTI Giorgio V.,DI MAIO Massimo,BUTTIGLIERO Consuelo

Publisher

Edizioni Minerva Medica

Subject

Urology,Nephrology

Link

https://www.minervamedica.it/pdf.php?cod=R19Y2021N06A0803

Reference75 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Adherence to hormonal deprivation therapy in prostate cancer in clinical practice: a retrospective, single-center study

3. Endocrine therapy for prostate cancer

4. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

5. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The relationship between LDH and GLIM criteria for cancer cachexia: Systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-07

2. Biological role and expression of translationally controlled tumor protein (TCTP) in tumorigenesis and development and its potential for targeted tumor therapy;Cancer Cell International;2024-06-04

3. A new method to quantify the effect of co-medication on the efficacy of abiraterone in metastatic castration-resistant prostate cancer patients;Frontiers in Pharmacology;2023-09-28

4. Intratumoral immune heterogeneity of prostate cancer characterized by typing and hub genes;Journal of Cellular and Molecular Medicine;2022-12-16

5. Long-term prognosis and prognostic factors of brachytherapy and propensity score matched comparisons of the outcomes between brachytherapy and radical prostatectomy: a retrospective cohort study;Translational Andrology and Urology;2022-12